All sponsors

Hangzhou Highlightll Pharmaceutical Co., Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING1
READOUTS ≤12 MONTHS3
Open Hangzhou Highlightll Pharmaceutical Co., Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
TLL-018 tablets
NCT06396026
P3Active, not recruitingChronic Spontaneous Urticaria4402025-10-23 (-5 mo)
TLL-018
NCT06887127
P3Active, not recruitingRheumatoid Arthritis3502026-12-31
HL-300
NCT07629778
P1/2RecruitingAtopic Dermatitis1562027-06-30
TLL-018
NCT07748728
P2Enrolling by invitationRheumatoid Arthritis (RA)902027-07-31
TLL-018
NCT07665996
P1/2Not yet recruitingChronic Spontaneous Urticaria (CSU)362027-12-31
TLL-018 tablets
NCT07764003
P2Not yet recruitingChronic Spontaneous Urticaria (CSU)1402027-12-31
TLL-018 tablets
NCT07784816
P2/3Not yet recruitingAtopic Dermatitis (AD)3902029-09-30